Alliance Pharma PLC Director Dealing (6659G)
20 Luglio 2023 - 10:54AM
UK Regulatory
TIDMAPH
RNS Number : 6659G
Alliance Pharma PLC
20 July 2023
20 July 2023
ALLIANCE PHARMA PLC
("Alliance" or the " Company ")
Director Dealing
Alliance Pharma plc (AIM: APH), the international healthcare
group , has been notified that Jo LeCouilliard, the non-executive
Chair of the Company, purchased 40,957 ordinary shares of 1.0p each
in the Company ("Ordinary Shares") at a price of 48.8 pence per
share on 20(th) July 2023.
Following this transaction, (i) Jo LeCouilliard's total
beneficial interest in the Company is 40,957 Ordinary Shares,
representing 0.008% of the Company's issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Jo LeCouilliard
-------------------------------------- ---------------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------------------------
a) Position/status Non-executive Chair, PDMR
-------------------------------------- ---------------------------------------------------
b) Initial notification Initial Notification
/Amendment
-------------------------------------- ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------------------------
a) Name Alliance Pharma Plc
-------------------------------------- ---------------------------------------------------
b) Legal Entity 213800RYIWZA4Q5WPZ13
Identifier
-------------------------------------- ---------------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------------------------
a) Description Ordinary shares of 1 pence each
of the financial
instrument,
type of instrument
Identification
code GB0031030819
-------------------------------------- ---------------------------------------------------
b) Nature of Purchase of shares
the transaction
-------------------------------------- ---------------------------------------------------
c) Currency GBP
-------------------------------------- ---------------------------------------------------
d) Price(s) Price(s) Volume(s)
and volume(s)
-------------------------------------- ----------------------- --------------------------
48.8 40,957
------------------------------------------- ----------------------- --------------------------
e) Aggregated
information 40,957 Ordinary Shares, bought at a price of
- Aggregated 48.8 pence per share, totalling GBP 19,987.02.
volume
- Price
- Aggregated
total
-------------------------------------- ---------------------------------------------------
f) Date of the 20 July 2023
transaction
-------------------------------------- ---------------------------------------------------
g) Place of London Stock Exchange, AIM
the transaction
-------------------------------------- ---------------------------------------------------
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Cora McCallum, Head of Investor Relations
& Corporate Communications + 44 (0)1249 705168
ir@allianceph.com
Buchanan + 44 (0)20 7466 5000
Mark Court / Hannah Ratcliff
alliancepharma@buchanan.uk.com
Numis Securities Limited (Nominated Adviser
and Joint Broker) + 44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Sher
Shah
Investec Bank plc (Joint Broker) + 44 (0)20 7597 5970
Patrick Robb / Maria Gomez de Olea
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare
company. Our purpose is to empower people to make a positive
difference to their health and wellbeing by making our trusted and
proven brands available around the world.
We deliver organic growth through investing in our priority
brands and channels, in related innovation, and through selective
geographic expansion to increase the reach of our brands.
Periodically, we may look to enhance our organic growth through
selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 285 people
based in locations across Europe, North America, and the Asia
Pacific region. By outsourcing our manufacturing and logistics we
remain asset-light and focused on maximising the value we can
bring, both to our stakeholders and to our brands.
For more information on Alliance, please visit our website :
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHVBLBLXDLEBBL
(END) Dow Jones Newswires
July 20, 2023 04:54 ET (08:54 GMT)
Grafico Azioni Alliance Pharma (LSE:APH)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Alliance Pharma (LSE:APH)
Storico
Da Mag 2023 a Mag 2024